跳至主要内容
临床试验/NL-OMON40478
NL-OMON40478已完成4 期

VICTORY AF evaluation of multielectrode phased RF technology in persistent Atrial Fibrilation - VICTORY AF

Medtronic0 个研究点目标入组 20 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
已完成
发起方
Medtronic
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • * History of symptomatic persistent or long-standing persistent atrial fibrillation defined as:
  • o Persistent AF: sustained AF lasting > 7 days and less than one year, or lasting <
  • 7 days but necessitating pharmacologic or electrical cardioversion; OR
  • o Long-standing persistent AF: sustained AF lasting at least 1 year, but no more
  • than 4 years in duration.
  • o Continuous AF as demonstrated on a 48-hour Holter at baseline
  • o AF symptoms defined as the manifestation of:
  • * Palpitations
  • * Exertional dyspnea
  • * Increased intolerance to routine activities (exercise intolerance)
  • * Age between 18 and 70
  • * Failure of at least one class I or III rhythm control AAD

排除标准

  • Structural heart disease of clinical significance including:
  • o Previous cardiac surgery other than CABG or mitral valve repair
  • o NYHA Class III or IV CHF and/or documented ejection fraction <40%
  • measured by acceptable cardiac testing
  • o Left atrial diameter of >55mm
  • o Moderate to severe mitral or aortic valvular heart disease
  • o Stable/unstable angina or ongoing myocardial ischemia
  • o Myocardial infarction (MI) within three months of enrollment
  • o Congenital heart disease other than ASD or PFO without a right to left shunt
  • where the underlying abnormality increases the risk of an ablative procedure
  • o Prior ASD or PFO closure with a device using a percutaneous approach
  • o Hypertrophic cardiomyopathy (LV septal wall thickness >1.5 cm)
  • o Pulmonary hypertension (mean or systolic PA pressure >50mm Hg on Doppler
  • * Any prior ablation for atrial fibrillation in the left atrium
  • * Enrollment in any other ongoing arrhythmia study protocol
  • * Any ventricular tachyarrhythmia currently being treated where the arrhythmia or the
  • management may interfere with this study
  • * Active infection or sepsis
  • * Any history of cerebral vascular disease including stroke or TIAs
  • * Pregnancy or lactation
  • * Left atrial thrombus at the time of ablation
  • * Untreatable allergy to contrast media
  • * Any diagnosis of atrial fibrillation secondary to electrolyte imbalance, thyroid disease, or
  • any other reversible or non-cardiovascular causes
  • * History of blood clotting (bleeding or thrombotic) abnormalities
  • * Known sensitivities to heparin or vitamin K antagonists (ie. Warfarin/Coumadin)
  • * Prescribed to direct thrombin or factor inhibitors
  • * Severe COPD (defined as an FEV1 <1)
  • * Severe co-morbidity or poor general physical/mental health that, in the opinion of the
  • Investigator, will not allow the subject to be a good study candidate (i.e. other disease
  • processes, mental capacity, substance abuse, shortened life expectance, etc.)
  • * MRI contraindicated
  • * Any invasive cardiovascular procedure performed or planned within the 3 month period
  • prior to the ablation procedure

研究者

发起方
Medtronic

相似试验